Critical Path Institute (C-Path)‘s nonprofit drug accelerator, TRxA, offers selected BRIDGe awardees a comprehensive suite of resources, including:
- Funding to advance drug development initiatives.
- Strategic and tactical expertise in drug discovery and development, including regulatory science considerations.
- Resources and hands-on guidance, collaborating closely with academic researchers to develop comprehensive data packages for potential drug candidates, a key to garnering interest from biotechnology and pharmaceutical companies to invest in clinical trials.
For this RFP, eligible platforms include small molecules, protein-based therapeutics, and in vivo gene-based therapies. TRxA is accepting applications for projects in brain health, pediatrics, and rare and orphan diseases.